IPCA Laboratories signs an agreement with Medicines for Malaria Venture

IPCA Laboratories (IPCA) announced on Friday that it had entered into an agreement with Medicines for Malaria Venture to co-develop an antimalarial co-formulation called 'Atoguanil'.

Based on proprietary IPCA technology, Atoguanil contains the active pharmaceutical ingredients, namely, atovaquone and proguanil. The manufacturing cost of the former is believed to be a major hindrance in the use of atovaquone and proguanil-based products in malaria-endemic nations. However, the antimalarial co-formulation, if co-developed, has the potential to provide a lower-cost alternative and it will also boost the availability of these much-needed products in malaria-endemic countries.

IPCA Laboratories Limited is a company, engaged in pharmaceuticals business. It manufactures and supplies over 10 active pharmaceutical ingredients (APIs) and offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate, and zaltoprofen.

By the time the market closed on Friday, the stock was trading at Rs 1,134.25, down by 0.40 per cent or Rs 4.55 per share. The 52-week high was recorded at Rs 1,188 and the 52-week low was recorded at Rs 717.95